Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) CEO Oren Gilad purchased 5,500 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were bought at an average price of $1.84 per share, for a total transaction of $10,120.00. Following the purchase, the chief executive officer now directly owns 345,620 shares in the company, valued at $635,940.80. This represents a 1.62 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Aprea Therapeutics Price Performance
APRE stock opened at $1.70 on Friday. The company has a market capitalization of $9.34 million, a P/E ratio of -0.60 and a beta of 1.04. Aprea Therapeutics, Inc. has a 12 month low of $1.67 and a 12 month high of $6.48. The firm's fifty day simple moving average is $2.81 and its 200-day simple moving average is $3.19.
Aprea Therapeutics (NASDAQ:APRE - Get Free Report) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.20. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.15 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. As a group, sell-side analysts forecast that Aprea Therapeutics, Inc. will post -2.55 earnings per share for the current year.
Analyst Ratings Changes
Several equities analysts recently issued reports on APRE shares. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research report on Wednesday, January 15th. Wedbush reissued an "outperform" rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, March 25th.
Read Our Latest Analysis on APRE
Institutional Trading of Aprea Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of APRE. BNP Paribas Financial Markets acquired a new position in Aprea Therapeutics in the fourth quarter valued at approximately $43,000. LPL Financial LLC acquired a new stake in shares of Aprea Therapeutics during the 4th quarter worth approximately $53,000. Landscape Capital Management L.L.C. purchased a new position in shares of Aprea Therapeutics during the 4th quarter valued at approximately $116,000. Finally, Stonepine Capital Management LLC lifted its stake in shares of Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company's stock valued at $491,000 after purchasing an additional 12,047 shares during the period. 34.19% of the stock is owned by institutional investors and hedge funds.
About Aprea Therapeutics
(
Get Free Report)
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
